Table 1 Baseline characteristics of patients enrolled in the study

Male, N(%)

16(61.5%)

27(61.4%)

0

0.988

Age (year)

8.01(3.97)

6.92(4.00)

1.098

0.276

Weight (kg)

30.02(16.06)

25.24(13.33)

1.343

0.184

ALT/ULN

3.38(2.24)

4.95(3.97)

−1.851

0.069

AST/ULN

2.35(1.60)

3.26(2.65)

−1.594

0.116

Log₁₀HBV DNA (IU/ml)

7.38(1.15)

7.46(1.03)

−0.306

0.761

HBsAg quantification (IU/ml)

38,575.9(51,834.5)

28,540.0(28,999.9)

0.935

0.354

HBeAg(s/co)

844.05(530.96)

910.67(497.47)

−0.528

0.599

HBV genotype (getotype B/genotype C/Undetected), N

11/6/9

21/13/10

1.208

0.547

Grade of inflammation in liver histology(G0–1/G2–3), N

10/16

22/22

0.877

0.349

Stage of fibrosis in liver histology(S0–1/S2–3), N

16/10

30/14

0.320

0.572

Treatment switch due to suboptimal HBV DNA reduce, N(%)

6(23.08%)

0(0%)

8.356

0.002